Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA-Binding Proteins | 24 | 2021 | 490 | 5.510 |
Why?
|
| Transcription Factors | 22 | 2021 | 524 | 4.850 |
Why?
|
| B-Lymphocytes | 14 | 2020 | 287 | 2.580 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2020 | 59 | 1.850 |
Why?
|
| Interferon-alpha | 3 | 2020 | 50 | 1.690 |
Why?
|
| Trans-Activators | 9 | 2009 | 118 | 1.500 |
Why?
|
| Lupus Erythematosus, Systemic | 7 | 2019 | 997 | 1.440 |
Why?
|
| Cell Differentiation | 6 | 2019 | 429 | 1.270 |
Why?
|
| Oncogenes | 8 | 2009 | 34 | 1.160 |
Why?
|
| B-Lymphocyte Subsets | 4 | 2019 | 30 | 1.130 |
Why?
|
| Hematopoiesis | 2 | 2015 | 25 | 0.810 |
Why?
|
| Gene Expression | 5 | 2020 | 417 | 0.780 |
Why?
|
| Dendritic Cells | 3 | 2019 | 144 | 0.760 |
Why?
|
| Erythropoiesis | 1 | 2021 | 9 | 0.710 |
Why?
|
| Chromatin | 1 | 2021 | 76 | 0.670 |
Why?
|
| Toll-Like Receptors | 1 | 2020 | 22 | 0.650 |
Why?
|
| Flow Cytometry | 6 | 2020 | 292 | 0.620 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 137 | 0.560 |
Why?
|
| Cell Lineage | 4 | 2015 | 53 | 0.540 |
Why?
|
| Neutrophils | 1 | 2018 | 185 | 0.520 |
Why?
|
| Precursor Cells, B-Lymphoid | 2 | 2014 | 12 | 0.500 |
Why?
|
| Mice | 16 | 2015 | 4846 | 0.490 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2006 | 10 | 0.470 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 645 | 0.460 |
Why?
|
| Antibody Formation | 3 | 2014 | 77 | 0.450 |
Why?
|
| Protein-Tyrosine Kinases | 5 | 2009 | 97 | 0.410 |
Why?
|
| Lymphopoiesis | 2 | 2011 | 22 | 0.400 |
Why?
|
| Kidney | 1 | 2015 | 289 | 0.400 |
Why?
|
| Animals | 17 | 2015 | 10758 | 0.380 |
Why?
|
| Humans | 22 | 2021 | 29089 | 0.380 |
Why?
|
| Gene Knockdown Techniques | 3 | 2021 | 134 | 0.360 |
Why?
|
| Serum Amyloid A Protein | 1 | 2011 | 2 | 0.360 |
Why?
|
| Antibodies, Antinuclear | 2 | 2014 | 183 | 0.340 |
Why?
|
| Pluripotent Stem Cells | 1 | 2010 | 8 | 0.330 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2021 | 130 | 0.320 |
Why?
|
| Autoimmunity | 2 | 2011 | 158 | 0.310 |
Why?
|
| Genes, Immunoglobulin | 2 | 2006 | 10 | 0.290 |
Why?
|
| Macrophages | 1 | 2011 | 307 | 0.290 |
Why?
|
| Adult | 5 | 2020 | 8081 | 0.280 |
Why?
|
| Bacterial Toxins | 1 | 2011 | 276 | 0.280 |
Why?
|
| Autoantibodies | 1 | 2011 | 486 | 0.280 |
Why?
|
| Transcriptional Activation | 2 | 2005 | 86 | 0.270 |
Why?
|
| Transcription, Genetic | 6 | 2014 | 405 | 0.270 |
Why?
|
| Mice, Transgenic | 4 | 2011 | 514 | 0.270 |
Why?
|
| Transcription Factors, TFII | 2 | 2009 | 4 | 0.260 |
Why?
|
| Cell Proliferation | 1 | 2010 | 827 | 0.260 |
Why?
|
| Mice, Inbred C57BL | 5 | 2011 | 1672 | 0.250 |
Why?
|
| Immunologic Techniques | 1 | 2006 | 12 | 0.250 |
Why?
|
| Mice, Knockout | 3 | 2015 | 876 | 0.250 |
Why?
|
| Lymphoid Tissue | 1 | 2006 | 9 | 0.240 |
Why?
|
| Cells, Cultured | 3 | 2016 | 1022 | 0.240 |
Why?
|
| Middle Aged | 4 | 2020 | 7458 | 0.230 |
Why?
|
| Cytokines | 2 | 2020 | 456 | 0.230 |
Why?
|
| Promoter Regions, Genetic | 4 | 2014 | 344 | 0.230 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 276 | 0.230 |
Why?
|
| Cell Line | 4 | 2015 | 701 | 0.220 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 468 | 0.220 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 2004 | 1 | 0.220 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 557 | 0.220 |
Why?
|
| Signal Transduction | 3 | 2020 | 1483 | 0.200 |
Why?
|
| Female | 7 | 2020 | 15747 | 0.190 |
Why?
|
| Mice, SCID | 2 | 2014 | 60 | 0.190 |
Why?
|
| Mice, Inbred NOD | 2 | 2014 | 50 | 0.190 |
Why?
|
| Case-Control Studies | 2 | 2014 | 740 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 329 | 0.180 |
Why?
|
| Aged | 3 | 2018 | 5627 | 0.180 |
Why?
|
| Fetal Globulins | 1 | 2021 | 3 | 0.180 |
Why?
|
| K562 Cells | 1 | 2021 | 20 | 0.180 |
Why?
|
| Base Sequence | 4 | 2011 | 589 | 0.170 |
Why?
|
| CRISPR-Cas Systems | 1 | 2021 | 52 | 0.170 |
Why?
|
| In Vitro Techniques | 2 | 2015 | 242 | 0.170 |
Why?
|
| Binding Sites | 4 | 2006 | 355 | 0.170 |
Why?
|
| CpG Islands | 1 | 2020 | 26 | 0.160 |
Why?
|
| Protein Structure, Tertiary | 3 | 2006 | 284 | 0.160 |
Why?
|
| Ligands | 1 | 2020 | 178 | 0.160 |
Why?
|
| Stem Cells | 2 | 2015 | 123 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 257 | 0.150 |
Why?
|
| Adult Stem Cells | 1 | 2019 | 10 | 0.150 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2019 | 2 | 0.150 |
Why?
|
| Male | 6 | 2018 | 14056 | 0.150 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2019 | 30 | 0.150 |
Why?
|
| Antibodies | 2 | 2011 | 125 | 0.150 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2019 | 24 | 0.150 |
Why?
|
| Transcriptome | 2 | 2018 | 244 | 0.150 |
Why?
|
| Plasma Cells | 1 | 2019 | 21 | 0.150 |
Why?
|
| Blotting, Western | 2 | 2011 | 515 | 0.140 |
Why?
|
| Immunologic Memory | 1 | 2019 | 58 | 0.140 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 115 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 681 | 0.140 |
Why?
|
| Recombinant Proteins | 2 | 2011 | 417 | 0.130 |
Why?
|
| Young Adult | 2 | 2014 | 2856 | 0.130 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 1057 | 0.130 |
Why?
|
| Mutation | 3 | 2011 | 873 | 0.130 |
Why?
|
| Disease Progression | 1 | 2018 | 481 | 0.120 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2016 | 7 | 0.120 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2016 | 24 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2018 | 234 | 0.120 |
Why?
|
| Transduction, Genetic | 1 | 2015 | 28 | 0.120 |
Why?
|
| Fetal Blood | 1 | 2015 | 40 | 0.120 |
Why?
|
| Oryzias | 1 | 2015 | 4 | 0.120 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2014 | 50 | 0.110 |
Why?
|
| Nuclear Proteins | 2 | 2011 | 249 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 194 | 0.110 |
Why?
|
| Amino Acid Sequence | 2 | 2008 | 697 | 0.110 |
Why?
|
| Cell Division | 1 | 2015 | 154 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 270 | 0.110 |
Why?
|
| Homeodomain Proteins | 2 | 2014 | 79 | 0.110 |
Why?
|
| Immunoglobulins | 1 | 2014 | 34 | 0.110 |
Why?
|
| Antigens, Surface | 1 | 2014 | 39 | 0.110 |
Why?
|
| CHO Cells | 2 | 2005 | 96 | 0.110 |
Why?
|
| Immunophenotyping | 1 | 2014 | 61 | 0.110 |
Why?
|
| Cricetinae | 2 | 2005 | 131 | 0.110 |
Why?
|
| RNA Interference | 2 | 2014 | 137 | 0.100 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2014 | 2 | 0.100 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2014 | 3 | 0.100 |
Why?
|
| Transfection | 2 | 2005 | 319 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2014 | 71 | 0.100 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2014 | 136 | 0.100 |
Why?
|
| DNA | 2 | 2004 | 378 | 0.090 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 1360 | 0.090 |
Why?
|
| Databases, Protein | 1 | 2012 | 22 | 0.090 |
Why?
|
| Antigens, CD19 | 2 | 2008 | 14 | 0.090 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 45 | 0.090 |
Why?
|
| Protective Agents | 1 | 2011 | 17 | 0.090 |
Why?
|
| Cell Separation | 1 | 2011 | 57 | 0.090 |
Why?
|
| Cell Death | 1 | 2011 | 119 | 0.090 |
Why?
|
| Spleen | 1 | 2011 | 114 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1009 | 0.080 |
Why?
|
| Genes, Lethal | 1 | 2011 | 6 | 0.080 |
Why?
|
| Phosphorylcholine | 1 | 2011 | 11 | 0.080 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2011 | 10 | 0.080 |
Why?
|
| Lymphocyte Activation | 2 | 2009 | 214 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 278 | 0.080 |
Why?
|
| Genes, Dominant | 1 | 2010 | 35 | 0.080 |
Why?
|
| Computational Biology | 1 | 2012 | 156 | 0.080 |
Why?
|
| Teratoma | 1 | 2010 | 17 | 0.080 |
Why?
|
| Antigens, Bacterial | 1 | 2011 | 166 | 0.080 |
Why?
|
| Bacillus anthracis | 1 | 2011 | 154 | 0.080 |
Why?
|
| Cell Survival | 1 | 2011 | 420 | 0.080 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2009 | 35 | 0.070 |
Why?
|
| Membrane Microdomains | 1 | 2009 | 40 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 285 | 0.070 |
Why?
|
| Tretinoin | 1 | 2008 | 17 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2009 | 585 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 465 | 0.070 |
Why?
|
| Leukocyte Common Antigens | 1 | 2007 | 17 | 0.060 |
Why?
|
| Glomerulonephritis | 1 | 2007 | 16 | 0.060 |
Why?
|
| Biomarkers | 1 | 2010 | 787 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 285 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2007 | 202 | 0.060 |
Why?
|
| Chickens | 1 | 2006 | 62 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2006 | 50 | 0.060 |
Why?
|
| Organ Specificity | 1 | 2006 | 83 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2006 | 85 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 170 | 0.060 |
Why?
|
| Cricetulus | 1 | 2005 | 56 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2005 | 66 | 0.060 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 66 | 0.060 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 68 | 0.060 |
Why?
|
| Genes, Reporter | 1 | 2005 | 87 | 0.050 |
Why?
|
| Protein Structure, Quaternary | 1 | 2004 | 26 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2005 | 68 | 0.050 |
Why?
|
| Dimerization | 1 | 2004 | 76 | 0.050 |
Why?
|
| Antigens | 2 | 2019 | 68 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2005 | 120 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 132 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2005 | 91 | 0.050 |
Why?
|
| Consensus Sequence | 1 | 2004 | 17 | 0.050 |
Why?
|
| Cell Line, Transformed | 1 | 2004 | 42 | 0.050 |
Why?
|
| Germinal Center | 1 | 2004 | 24 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2006 | 668 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2004 | 137 | 0.050 |
Why?
|
| Protein Binding | 3 | 2014 | 667 | 0.050 |
Why?
|
| Nuclear Matrix | 1 | 2002 | 1 | 0.050 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2002 | 8 | 0.050 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2002 | 4 | 0.050 |
Why?
|
| 5' Untranslated Regions | 1 | 2002 | 9 | 0.050 |
Why?
|
| Haplotypes | 2 | 2014 | 289 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2002 | 120 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 56 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2019 | 48 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2019 | 74 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 118 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 93 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 14 | 0.030 |
Why?
|
| Nanog Homeobox Protein | 1 | 2014 | 1 | 0.030 |
Why?
|
| Lewis X Antigen | 1 | 2014 | 2 | 0.030 |
Why?
|
| Cellular Reprogramming | 1 | 2014 | 11 | 0.030 |
Why?
|
| Alleles | 1 | 2014 | 357 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 198 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2014 | 149 | 0.020 |
Why?
|
| Encyclopedias as Topic | 1 | 2012 | 1 | 0.020 |
Why?
|
| Access to Information | 1 | 2012 | 8 | 0.020 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2011 | 24 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 108 | 0.020 |
Why?
|
| Internet | 1 | 2012 | 129 | 0.020 |
Why?
|
| Lipoylation | 1 | 2009 | 2 | 0.020 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2009 | 3 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2009 | 31 | 0.020 |
Why?
|
| Protein Transport | 1 | 2009 | 158 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 1594 | 0.020 |
Why?
|
| PAX5 Transcription Factor | 1 | 2008 | 2 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2008 | 15 | 0.020 |
Why?
|
| Retinoid X Receptors | 1 | 2008 | 24 | 0.020 |
Why?
|
| Retinoids | 1 | 2008 | 38 | 0.020 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2002 | 1 | 0.010 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2002 | 1 | 0.010 |
Why?
|
| Thymine | 1 | 2002 | 3 | 0.010 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2002 | 3 | 0.010 |
Why?
|
| Immunoglobulin Constant Regions | 1 | 2002 | 3 | 0.010 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2002 | 3 | 0.010 |
Why?
|
| Adenine | 1 | 2002 | 17 | 0.010 |
Why?
|
| Exons | 1 | 2002 | 43 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 314 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2002 | 202 | 0.010 |
Why?
|